Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced interim data from a phase 1b study of ABX1100 ...
A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and ...
The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...
Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...
A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...
(A and B) Preparation process of the self-assembly of peptide, DNR prodrug, and siRNA, along with the corresponding formulation ratios. (C) DLS detection of the particle size of PDR at different ...
A randomized, clinical trial testing vutrisiran, a small-interfering RNA (siRNA) therapy for the treatment of cardiomyopathy resulting from transthyretin amyloidosis (ATTR-CM), has met its primary ...
Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results